143 related articles for article (PubMed ID: 35961619)
1. 18 F-FDG PET/CT in Urethral Metastases From Bladder Cancer.
Beyhan E; Baykal Koca S; Yücetaş U; Çermik TF; Ergül N
Clin Nucl Med; 2022 Nov; 47(11):e713-e714. PubMed ID: 35961619
[TBL] [Abstract][Full Text] [Related]
2. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
[TBL] [Abstract][Full Text] [Related]
3. Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique.
Nayak B; Dogra PN; Naswa N; Kumar R
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):386-93. PubMed ID: 23179944
[TBL] [Abstract][Full Text] [Related]
4. Staging
Voskuilen CS; van Gennep EJ; Einerhand SMH; Vegt E; Donswijk ML; Bruining A; van der Poel HG; Horenblas S; Hendricksen K; van Rhijn BWG; Mertens LS
Eur Urol Oncol; 2022 Jun; 5(3):366-369. PubMed ID: 33583752
[TBL] [Abstract][Full Text] [Related]
5. Integrated analysis of
Girard A; Rouanne M; Taconet S; Radulescu C; Neuzillet Y; Girma A; Beaufrere A; Lebret T; Le Stanc E; Grellier JF
Eur Radiol; 2019 Aug; 29(8):4286-4293. PubMed ID: 30666449
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis.
Soubra A; Hayward D; Dahm P; Goldfarb R; Froehlich J; Jha G; Konety BR
World J Urol; 2016 Sep; 34(9):1229-37. PubMed ID: 26847182
[TBL] [Abstract][Full Text] [Related]
7. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer.
Goodfellow H; Viney Z; Hughes P; Rankin S; Rottenberg G; Hughes S; Evison F; Dasgupta P; O'Brien T; Khan MS
BJU Int; 2014 Sep; 114(3):389-95. PubMed ID: 24341486
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
Verghote F; Poppe L; Verbeke S; Dirix P; Albersen M; De Meerleer G; Berghen C; Ost P; Villeirs G; De Visschere P; De Man K; De Maeseneer D; Rottey S; Van Praet C; Decaestecker K; Fonteyne V
BMC Cancer; 2021 Oct; 21(1):1113. PubMed ID: 34663254
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
[TBL] [Abstract][Full Text] [Related]
12. The evolution of PET imaging in renal, bladder, upper urinary tract urothelial, testicular and penile carcinoma - Today's impact, tomorrow's potential.
Urso L; Bauckneht M; Albano D; Chondrogiannis S; Grassetto G; Lanfranchi F; Dondi F; Fornarini G; Lazzeri M; Evangelista L
Expert Rev Med Devices; 2024; 21(1-2):55-72. PubMed ID: 38072680
[TBL] [Abstract][Full Text] [Related]
13. Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and
Vind-Kezunovic S; Bouchelouche K; Ipsen P; Høyer S; Bell C; Bjerggaard Jensen J
Eur Urol Focus; 2019 Jan; 5(1):90-96. PubMed ID: 28753817
[TBL] [Abstract][Full Text] [Related]
14. Clinical Utility of
Das JP; Vargas HA; Ghafoor S; Goh AC; Ulaner GA
J Nucl Med; 2021 May; 62(5):643-647. PubMed ID: 32948680
[TBL] [Abstract][Full Text] [Related]
15. Is [F-18]-fluorodeoxyglucose FDG-PET/CT better than ct alone for the preoperative lymph node staging of muscle invasive bladder cancer?
Uttam M; Pravin N; Anish B; Nandita K; Arup M
Int Braz J Urol; 2016; 42(2):234-41. PubMed ID: 27256176
[TBL] [Abstract][Full Text] [Related]
16. Pelvic Lymph Node Staging by Combined
Pichler R; De Zordo T; Fritz J; Kroiss A; Aigner F; Heidegger I; Virgolini I; Horninger W; Uprimny C
Clin Genitourin Cancer; 2017 Jun; 15(3):e387-e395. PubMed ID: 27601364
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting the accuracy of
Kutluturk K; Simsek A; Comak A; Gonultas F; Unal B; Kekilli E
Niger J Clin Pract; 2019 Jan; 22(1):63-68. PubMed ID: 30666022
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
Swinnen G; Maes A; Pottel H; Vanneste A; Billiet I; Lesage K; Werbrouck P
Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Value of
Voskuilen CS; Schweitzer D; Jensen JB; Nielsen AM; Joniau S; Muilwijk T; Necchi A; Azizi M; Spiess PE; Briganti A; Bandini M; Goffin K; Bouchelouche K; van Werkhoven E; Shariat SF; Xylinas E; Azawi NH; Ku JH; Foerster B; van Rhijn BWG; Vegt E; Hendricksen K
Eur Urol Oncol; 2020 Feb; 3(1):73-79. PubMed ID: 31591037
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma.
Kibel AS; Dehdashti F; Katz MD; Klim AP; Grubb RL; Humphrey PA; Siegel C; Cao D; Gao F; Siegel BA
J Clin Oncol; 2009 Sep; 27(26):4314-20. PubMed ID: 19652070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]